BlueRock Therapeutics announces first patient receives investigational therapy in Phase 1/2a clinical trial of OpCT-001 for the treatment of primary photoreceptor diseases
'The initiation of the CLARICO trial represents a key milestone for the OpCT-001 program,' said Amit Rakhit, MD, MBA, BlueRock's Chief Development and Medical Officer. 'We believe OpCT-001 holds significant promise as a novel therapeutic approach for restoring vision in people living with primary photoreceptor diseases, and we look forward to assessing its safety and tolerability profile as we advance this important program in our pipeline.'
CLARICO is a Phase 1/2a first-in-human, multisite, 2-part interventional study to evaluate the safety, tolerability, and the effect on clinical outcomes of OpCT-001 in up to approximately 54 adults with primary photoreceptor disease. Phase 1 will focus on safety and includes a dose-escalation design. Phase 2 is designed to gather additional safety data and assess the effect of OpCT-001 on measures of visual function, functional vision, and anatomic measures of engraftment in different clinical subgroups.
'We aim to transform treatment options for patients facing irreversible vision loss. OpCT-001, our investigational iPSC-derived cell therapy, has the potential to restore vision for individuals with primary photoreceptor disease,' said Christian Rommel, Executive Vice President and Global Head of Research and Development of the Pharmaceuticals Division at Bayer. 'We are excited to announce the first patient in the CLARICO trial, the first-ever clinical trial for an iPSC-derived treatment in this field.'
Primary photoreceptor diseases affect the structure and function of the photoreceptor cells in the retina, leading to irreversible vision loss in both children and adults. OpCT-001 aims to restore vision in patients with primary photoreceptor diseases by replacing degenerated cells in the retina with functional cells. Limited treatment options currently exist for treating primary photoreceptor diseases which affect an estimated 110,000 people in the U.S. 1
OpCT-001 is an investigational cell therapy that has not been approved by any regulatory authority, and its efficacy and safety have not been established or fully evaluated.
About CLARICO
CLARICO is a Phase 1/2a first-in-human, multisite, 2-part interventional study to evaluate the safety, tolerability, and the effect on clinical outcomes of OpCT-001 in up to approximately 54 adults with primary photoreceptor disease. Phase 1 will focus on safety and features a dose-escalation design. Phase 2 is designed to gather additional safety data and assess the effect of OpCT-001 on measures of visual function, functional vision, and anatomic measures of engraftment in different clinical subgroups. Phase 1 will include 4 planned dose levels to be administered across 4 cohorts (Cohorts 1 through 4). Dose escalation in Phase 1 will be conducted using a standard 3+3 scheme in which a total of 12 to 24 legally blind participants (~3 to 6 per cohort) will receive OpCT-001. Phase 2 is planned to enroll a maximum of 15 participants in 2 cohorts (Cohorts 5 and 6) to evaluate 2 dose levels of OpCT-001 that will be selected based on Phase 1 safety and tolerability data. Phase 2 participants will be randomized 1:1 to either Cohort 5 or Cohort 6. Phase 2 participants and the investigator/study site personnel outside of the surgical team will be masked to OpCT-001 dose assignments. Further details of the trial can be found at www.clinicaltrials.gov (NCT06789445).
About BlueRock Therapeutics LP
BlueRock Therapeutics LP is a clinical stage cell therapy company focused on creating cellular medicines to treat devastating diseases. We are harnessing the power of cell therapy to create a pipeline of new medicines for people suffering from neurological and ophthalmic diseases. Two of our novel investigational cell therapies, bemdaneprocel (BRT-DA01) for the treatment of Parkinson's disease and OpCT-001 for the treatment of primary photoreceptor diseases are clinical stage programs. Bemdaneprocel has RMAT (Regenerative Medicine Advanced Therapy) and Fast Track designation from the US FDA (Food and Drug Administration) and is being tested in a Phase 3 clinical trial, exPDite-2. OpCT-001 has Fast Track designation from the FDA and is being tested in a Phase 1 clinical trial, Clarico. BlueRock was founded in 2016 as a joint venture of Versant Ventures and Leaps by Bayer, the impact investing arm of Bayer AG that invests in paradigm-shifting breakthrough innovation. In late 2019, BlueRock became a wholly owned, independently operated subsidiary of Bayer AG. Our culture is defined by the courage to persist regardless of the challenge, the urgency to transform medicine and deliver hope, integrity guided by mission, and community-mindedness with the understanding that we are all part of something bigger than ourselves. For more information, visit www.bluerocktx.com.
About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, 'Health for all, Hunger for none,' the company's products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to www.bayer.com.
ime (2025-0082E)
Forward-Looking Statements BlueRock Therapeutics
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as 'anticipate,' 'believe,' 'forecast,' 'estimate,' 'plan,' and 'intend,' among others. These forward-looking statements are based on BlueRock's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the initiation, timing, progress, activities, goals and reporting of results of any preclinical programs and clinical trials and research and development programs, the potential benefits, timing and future operation of the agreements with FUJIFILM Cellular Dynamics and Opsis Therapeutics, the ability to advance therapies into, and successfully initiate, enroll and complete clinical trials, the potential clinical utility of product candidates, the regulatory pathway of, and the timing or likelihood of any regulatory filings and approvals for, any product candidates, and the ability to, and extent of, potentially commercializing any product candidate, are forward looking. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Except as expressly required by law, BlueRock does not undertake an obligation to update or revise any forward-looking statement. All of BlueRock's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date hereof.
Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
Calix Announces CommandIQ 3.0: Evolving the Ultimate Subscriber Engagement App for the AI Era
Enabling intelligent personalization, seamless self-service, and promotion banners, the third generation of CommandIQ is designed to become a direct, regular touchpoint with subscribers—driving loyalty, brand affinity, and revenue for broadband experience providers LONDON & SAN JOSE, Calif., July 08, 2025--(BUSINESS WIRE)--Today, Calix, Inc. (NYSE: CALX) announced the third generation of its subscriber-facing CommandIQ® mobile app—smarter, more intuitive, and highly customizable to deliver exceptional experiences in the AI era. CommandIQ will be the routine touchpoint for residential subscribers to manage and control their smart homes. It puts the broadband service provider (BSP) brand front and center while delivering personalized value with every tap. Built on the Calix Broadband Platform and integrated with SmartLife™ managed services—including SmartHome™ and SmartMDU™—CommandIQ simplifies service delivery and creates new cross-sell and upsell opportunities to boost average revenue per user (ARPU), deepen engagement, and build long-term loyalty. Capabilities launching this year include a redesigned user interface (UI) with deeper personalization, and seamless application prioritization and billing. Continuous updates will ensure the app remains relevant and engaging, giving subscribers easy access to the services they care about most. According to Calix Market Insights, subscribers today expect effortless experiences, responsive support, and personalization across every interaction—from onboarding to troubleshooting. These trends mean BSPs must deliver smarter, more secure residential Wi-Fi experiences. The CommandIQ app is a direct engagement channel that enables subscribers to manage their smart homes and control their digital lives—monitoring everything from cybersecurity to kids' online time. Broadband providers that offer a branded app can leverage it as a powerful growth engine as they evolve into broadband experience providers (BXPs), capable of serving every internet need in their community. To encourage frequent engagement with a BSP's brand, the third generation of the CommandIQ app will offer: Promotion and announcement tiles to drive cross-sell and upsell opportunities. Upcoming CommandIQ enhancements will enable BSPs to actively engage with subscribers by posting banners and messages directly on the app's home screen, cutting through the noise and ensuring important communications reach subscribers effectively. A redesigned UI that offers subscribers seamless self-installation, built-in cybersecurity, and easy access to billing, support, and managed services. The new UI for CommandIQ will provide subscribers with a centralized command center to access billing, support, promotions, announcements, and SmartHome managed services. Built-in cybersecurity, parental controls, Calix GigaSpire® self-installation and self-upgrade, and optimization tools put subscribers in control—reducing support calls and truck rolls. Intelligent personalization that helps subscribers prioritize their smart home experiences. New capabilities like MyPrioritiesIQ™ will allow subscribers to intelligently prioritize activities like gaming, streaming, and remote work to optimize their in-home network experience. An app remains a powerful advantage for BSPs—subscribers with strong Wi-Fi and an intuitive app are 54 percent more likely to recommend their provider, according to Calix Market Insights. Since 2019, CommandIQ has offered BSPs a simple path to a fully branded app: CTC achieved 85 percent app adoption in Minnesota, doubling growth and cutting truck rolls in half with seamless self-installation through CommandIQ. GoFibre is anchoring their residential expansion in Scotland and Northern England with a localized CommandIQ experience. OC Fiber boosted customer lifetime value 30 percent in one week with new Wi-Fi packages and a branded app for their Indiana subscribers. Sprout Fiber Internet is strengthening subscriber engagement and satisfaction in Alabama with CommandIQ and more personalization. "Ease of use and personalization create better experiences—for both marketers and subscribers," said Bonnie Baty, marketing and services manager at Sprout Fiber Internet, a division of Cullman Electric Cooperative. "The redesigned CommandIQ app will make it easier for us to stay connected with subscribers in a more personalized and effective way. At the same time, the streamlined user interface empowers subscribers to manage their own experiences with features like the quick links carousel for billing and support, and enhanced smart home device management. As we prepare to deepen subscriber engagement and grow the experiences we offer, CommandIQ is essential." In late 2024, Calix expanded CommandIQ support to more than 160 third-party gateway models—enabling BSPs to deliver personalized, branded mobile apps for a consistent, high-quality subscriber experience at scale, regardless of the network hardware in use. "We have now made our subscriber-facing app so compelling that subscribers will want to engage with it regularly," said Michael Weening, president and chief executive officer at Calix. "In the AI era, we will continue to add new capabilities to make it even more powerful. As we prepare to launch the third generation of the Calix Broadband Platform later this year, we have timed these CommandIQ updates to set our customers up to win now. With the latest version of the app, they can elevate engagement across their service and marketing teams while growing revenue with cross-sell and upsell opportunities. All that value flows through the app—helping them cut through the noise and put their brand at the center of the home broadband experience." Learn how CommandIQ helps BSPs become broadband experience providers by delivering smarter, simpler, more personalized subscriber experiences at scale. About Calix Calix, Inc. (NYSE: CALX)—Calix is an appliance-based platform, cloud and managed services company. Broadband experience providers leverage Calix's broadband platform, cloud and managed services to simplify their operations, subscriber engagement and services; innovate for their consumer, business and municipal subscribers; and grow their value for members, investors and the communities they serve. Our end-to-end platform and managed services democratize the use of data – enabling our customers of any size to operate efficiently, acquire subscribers and deliver exceptional experiences. Calix is dedicated to driving continuous improvement in partnership with our growing ecosystem to support the transformation of our customers and their communities. This press release contains forward-looking statements that are based upon management's current expectations and are inherently uncertain. Forward-looking statements are based upon information available to us as of the date of this release, and we assume no obligation to revise or update any such forward-looking statement to reflect any event or circumstance after the date of this release, except as required by law. Actual results and the timing of events could differ materially from current expectations based on risks and uncertainties affecting Calix's business. The reader is cautioned not to rely on the forward-looking statements contained in this press release. Additional information on potential factors that could affect Calix's results and other risks and uncertainties are detailed in its quarterly reports on Form 10-Q and Annual Report on Form 10-K filed with the SEC and available at Calix and the Calix logo are trademarks or registered trademarks of Calix and/or its affiliates in the U.S. and other countries. A listing of Calix's trademarks can be found at Third-party trademarks mentioned are the property of their respective owners. View source version on Contacts Press Inquiries: Alison 919-353-4323Investor Inquiries: Nancy Fazioliinvestorrelations@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Wire
39 minutes ago
- Business Wire
Cyberlux Corporation Reports Q2 2025 Revenue of $24.5 Million, YTD Revenue of $29.6 Million, $18.1 Million Backlog, and Expanding Global Defense Footprint
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Cyberlux Corporation (OTC: CYBL), an advanced technology platform driving defense innovation and national security modernization, today announced financial results for the second quarter of 2025, reporting Q2 revenue of $24.5M bringing year-to-date (YTD) revenue to $29.6M. The company enters Q3 with a contracted order backlog of $18.1 million, underscoring continued momentum across all business units and providing strong visibility into the remainder of the fiscal year. During Q2, Cyberlux also achieved several key operational milestones: Successfully completed a major Unmanned Aircraft Systems (UAS) contract for a U.S. defense partner; Expanded technology deployment and product shipments into the U.S. Indo-Pacific Command (INDOPACOM) area of operations; Continued support of deployed tactical capabilities aiding Ukraine, reinforcing the company's role in frontline defense operations. 'Our Q2 results demonstrate the strength of our platform and the global relevance of our solutions,' said Mark Schmidt, CEO of Cyberlux Corporation. 'We are executing on all fronts—from contract fulfillment and system delivery to strategic expansion into key geographic theaters. These efforts are reflected in our revenue growth and $18.1 million backlog, which gives us a strong runway into the second half of the year.' Cyberlux continues to build momentum across its three core business units— Unmanned Systems, Tactical Solutions, and Infrastructure Technology —and remains a trusted supplier to both U.S. defense agencies and allied nations. With robust partnerships and government contract performance in place, the company is delivering high-impact solutions for the evolving modern battlefield. 'Cyberlux remains mission-driven—delivering real-time innovation, supporting critical U.S. and allied operations, and building long-term shareholder value,' added Schmidt. Cyberlux will provide additional insights and forecasts in its upcoming quarterly investor presentation, including updates on contract performance, technology deployments, and global partnerships. About Cyberlux Corporation Cyberlux Corporation (OTC: CYBL) is a leading provider of advanced defense technology solutions, specializing in tactical unmanned aerial systems (UAS), military communications and mission-critical solutions for global military markets. The company develops next-generation military capabilities designed to enhance operational effectiveness for U.S. military, government, and global defense partners. SAFE HARBOR STATEMENT This Press Release may contain forward-looking statements that can be identified by terminology such as 'believes,' 'expects,' 'potential,' 'plans,' 'suggests,' 'may,' 'should,' 'could,' 'intends,' or similar expressions within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's OTC/SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.
Business Wire
41 minutes ago
- Business Wire
Alcon's Latest Breakthrough Surgical Technology, Unity VCS, receives Health Canada approval
TORONTO--(BUSINESS WIRE)--Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced that UNITY® Vitreoretinal Cataract System (VCS) has received Health Canada approval. This innovation is the first to be introduced from Alcon's highly anticipated Unity portfolio. "This is a proud moment to see the world-class innovation from Alcon receive approval in Canada," said Dr. Rosa Braga-Mele, ophthalmologist and chair of Alcon's North America Cataract Core Advisory Board. Share 'Today marks an important day for Canadian ophthalmologists as we introduce the next generation of equipment solutions in cataract and vitreoretinal surgery, and we are grateful to those who helped us reach this milestone,' said Franck Leveiller, Head of Global R&D and Chief Scientific Officer, Alcon. 'We have a long legacy of engaging our customers throughout the research and development process to design bold innovations in ophthalmology. This approval is a significant milestone in delivering meaningful impact for Canadian Eye Care Professionals and patients.' Unity VCS is Alcon's most advanced vitreoretinal and cataract surgical innovations combined together in one integrated platform. Unity VCS is designed to deliver enhanced workflow efficiencies over Alcon's current leading systems, CONSTELLATION® Vision System for vitreoretinal and combined procedures, and CENTURION® Vision System with ACTIVE SENTRY® for cataract surgery. "The first time I used Unity VCS in a wet lab environment, I had a real 'wow' reaction," said Dr. Rosa Braga-Mele, ophthalmologist and chair of Alcon's North America Cataract Core Advisory Board. "This is a proud moment to see the world-class innovation from Alcon receive approval in Canada. I'm particularly excited about the stability of the fluidics and cutting efficiency of the platform, which is quite remarkable and will create considerable surgical efficiencies." Unity VCS leverages a novel phacoemulsification modality to deliver up to two times faster nucleus removal^ with 40% less energy* into the eye1, and a first-of-its-kind phaco handpiece that estimates temperature at the incision site3. In vitreoretinal advancements, the new technology offers cutting speeds of up to 30,000 cuts per minute, the world's fastest vitrectomy probe#,2,3. The platform offers surgical stability and efficiency with a unique proprietary fluidics system3. "As a global market leader in cataract and retina surgical products4,5,6, Alcon recognizes that the increasing demand for these procedures7,8,9 necessitates enhanced workflow efficiencies and excellent patient outcomes," said Jeroen Bastemeijer, General Manager, Alcon Canada. "Unity VCS builds on Alcon's expertise in surgical equipment with pioneering innovations for vitreoretinal and cataract surgery—driving advancements from cutting speeds to fluidics management, to ergonomics and workflow. We are thrilled to bring this latest breakthrough technology, Unity VCS, to Canadian clinics in 2026." Alcon has tested Unity VCS during investigational advisory wet lab sessions with more than 200 highly experienced surgeons from 30+ countries. Commercial launch of Unity VCS is expected in early 2026. Unity VCS is the latest innovation from the Alcon Vision Suite—a portfolio of innovative products designed to help Eye Care Professionals increase clinic and OR efficiency, and deliver exceptional patient experiences. The Alcon Vision Suite will continue to grow with cutting-edge Unity products that are expected to be introduced over the coming years, adding to our market-leading legacy products, which will continue to be available and serviceable. Unity VCS will be supported by Alcon's training, product maintenance, and Services teams. About Alcon Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at About UNITY VCS Indications / Intended Use3: The UNITY® VCS (Vitreoretinal Cataract System) console, when used with compatible devices, is indicated for use during anterior segment (i.e. phacoemulsification and removal of cataracts) and posterior segment (i.e. vitreoretinal) ophthalmic surgery. In addition, with the optional laser, this system is indicated for photocoagulation (i.e. vitreoretinal and macular pathologies), iridotomy and trabeculoplasty procedures. Please refer to the Directions for Use for the accessories/consumables and User Manual for a complete listing of indications, warnings, cautions and notes. ^2x faster nucleus removal than OZIL Torsional phaco *Based on N=10 HPs, Artificial cataract lens IOP 55 mmHg vacuum of 450 mmHg #Compared to Constellation HYPERVIT 20k vitrectomy probe OZIL - Trademarks are the property of their respective owners. References Alcon Data on File, 2024 - REF-24379. Alcon Data on File, 2024 - REF-24644. Unity VCS User Manual 2024 – REF-24980. Market Scope 2023 Retinal Surgical Device Market Report, 2023. Market Scope 2023 Cataract Surgical Equipment Market Report, 2023. Market Scope 2024 IOL Market Report, 2024. CNIB – Blindness in Canada, Accessed December 2, 2024 - REF-19527. The Prevalence of Canadian Vision Loss and Cataract Surgery, 2019 - REF-01661. Conference Board of Canada - Ophthalmology in Canada: Why Vision Loss Should Not Be Overlooked, 2020 - REF-10834. Connect with us on Facebook LinkedIn
